Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
(applications tested for the base form of this product only)
IL15 antibody was raised against synthetic peptide from N-Terminus of human IL15 (P40933). Percent identity by BLAST analysis: Human, Chimpanzee, Gorilla, Gibbon, Monkey, Marmoset, Mouse, Rat, Sheep, Panda, Cat, Bovine, Bat, Horse, Pig (100%); Elephant, Rabbit (92%); Galago, Guinea pig (85%).
LS-E20105 - Lyophilized - 100 µg - $145.00
Immunizing peptide used to generate LS-C102674. Useful for pre-absorption and neutralization of the antibody's antigen binding site.
Human IL15 / IL-15
Western Blot: Suggested dilution at 1µg/ml in 5% skim milk / PBS buffer, and HRP conjugated anti-Rabbit IgG should be diluted in 1: 50,000 - 100,000 as second antibody. ELISA titer in peptide based assay: 1:312500.
Lyophilized from PBS, 0.09% sodium azide, 2% sucrose
Centrifuge the vial prior to opening. Reconstitute with sterile distilled water to a concentration of 1 mg/ml. Vortex and centrifuge again.
Long term: -20°C, the use of 50% glycerol is recommended if storing aliquots in -20°C for long term use (up to 1 year); Short term (less than 1 week): 4°C. Avoid freeze-thaw cycles.
IL15 is a cytokine that regulates T and natural killer cell activation and proliferation. This cytokine and interleukine 2 share many biological activities. They are found to bind common hematopoietin receptor subunits, and may compete for the same receptor, and thus negatively regulate each other's activity. The number of CD8+ memory cells is shown to be controlled by a balance between this cytokine and IL2.